The numbers just dropped. They’re heavy. Eli Lilly has published the latest results for its experimental drug retatrutide and frankly, they are staggering. This isn’t a side-by-side comparison in a peer-reviewed journal yet—the trial was funded entirely by Lilly, remember—but the raw data suggests retatrutide might be the new king of weight loss.
It outperforms current giants like semaglutide (Ozempic) and tirzepatide (Zepbound). We’re talking effectiveness levels that rival bariatric surgery.
“The numbers are definitely impressive,” says Dr. Richard Siegel. “People have already been asking for it.”
He’s right. Everyone wants a shortcut.
How Much Did It Shed?
The study, dubbed TRIUMPH-1, ran for 80 weeks. It was a proper Phase 3 randomized double-blind placebo-controlled mess, involving more than 2,30 adults with obesity. They started low. 2 mg. Then they ramped up.
The results split by dosage look like this:
- 4 mg dose : 47.2 lbs lost. About 19% of body weight.
- 9 mg dose : 64.4 lbs lost. Roughly 26%.
- 12 mg dose : 70.3 lbs lost. That’s 28% of starting weight.
And here’s where it gets intense. A subgroup of about 500 participants with severe obesity (BMI of 35 or higher) continued for 104 weeks. On the maximum 12 mg dose, they shed an average of 85 pounds.
Eighty-five. That’s about 30% of their total body weight.
Over 65% of the people on that max dose dropped below a BMI of 30. They technically weren’t “obese” anymore according to the clinical definition.
Ania Jastreboff, the lead investigator from Yale, called it clinically meaningful. She wasn’t exaggerating. Nearly every participant saw significant loss.
The Cost Is Nausea (Usually)
You want to lose a sixth of your body? You’ll likely want to lie down for a few days. The side effect profile looks like the GLP-1 family photo.
Most participants reported:
– Nausea (29 to 42%)
– Diarrhea (25 to 0%)
– Constipation (24 to %
– Vomiting (11-25%)
But here is a twist.
More people in the placebo group dropped out because of side effects (4.9%) than those on the lowest actual drug dose (4.1%).
Weird. But Dr. Siegel pointed out a new concern: urinary tract infections. That isn’t common with Ozempic or Mounjaro. Something to watch.
Three Hormones, One Needle
What makes this drug different? It’s greedy. It grabs onto three different hormone receptors.
Semaglutide hits one: GLP-1.
Tirzepatide hits two: GLP-1 and GIP.
Retatrutide? It hits all three. GLP-1, GIP, and Glucagon (GCG).
It’s called a “triple G.” You take it once a week via injection. It slows your digestion and makes you full. Mir Ali, a doctor in California, argues that messing with three hormonal pathways at once explains the power. Weight isn’t controlled by just one switch. It’s a complex system. If you turn three dials, the machine runs differently.
The Race to The FDA
So where does it rank?
Previous trials for tirzepatide showed about 20-22% weight loss over 72 weeks. Semaglutide was around 15%. Retatrutide’s 28-30% is in another league.
But wait. No direct head-to-head test yet. The comparisons we have are between Tirzepatide and Semaglutide. Lilly funded that too, naturally, showing Tirzepatide beating Semaglutide.
“A head-to-head comparison is going be necessary to see actual long-term results,” Dr. Ali warns.
And then there’s reality. Clinical trial participants are usually more disciplined. They log everything. They don’t sneak a midnight snack while hiding in their cars.
“People in trials do better than anyone else,” says Dr. Siegel. “Real life is messy.”
Who Is This For?
Probably not you. Or me. Unless you’re truly carrying extra weight that hurts you.
Doctors agree. This isn’t for shedding five pounds for summer.
Dr. Ali : “This is for significant weight loss… people with severe obesity… other health conditions.”
Dr. Siegel : “Not everyone needs 25 to 3 weight loss.”
Overdoing it has its own problems. Muscle loss. Skin issues. Metabolic shifts.
When Can We Buy It?
Nowhere near yet.
Lilly hasn’t sent the data to the FDA. The drug is only legal inside a trial right now. People are trying to buy it online, of course. Good luck. That’s risky business.
The company expects the remaining Phase 3 trials to wrap up in 2026. They plan to submit the paperwork then. They are also testing it for diabetes and heart disease patients with obesity.
Until then? We wait.
The needle keeps turning. Whether the body keeps up, well.
